as 08-01-2025 4:00pm EST
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Upcoming Earnings Alert:
Get ready for potential market movements as Curis Inc. CRIS prepares to release earnings report on 05 Aug 2025.
Founded: | 2000 | Country: | United States |
Employees: | N/A | City: | LEXINGTON |
Market Cap: | 21.3M | IPO Year: | 2000 |
Target Price: | $16.50 | AVG Volume (30 days): | 130.8K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -6.03 | EPS Growth: | N/A |
52 Week Low/High: | $1.02 - $8.29 | Next Earning Date: | 08-05-2025 |
Revenue: | $11,202,000 | Revenue Growth: | 14.17% |
Revenue Growth (this year): | -0.38% | Revenue Growth (next year): | 9.52% |
CRIS Breaking Stock News: Dive into CRIS Ticker-Specific Updates for Smart Investing
GOBankingRates
2 months ago
GOBankingRates
2 months ago
GOBankingRates
2 months ago
Yahoo Finance
2 months ago
The Guardian
2 months ago
Yahoo Finance Video
2 months ago
Benzinga
2 months ago
Reuters
2 months ago
The information presented on this page, "CRIS Curis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.